Ethinyloestradiol 20 mcg with desogestrel 150 mcg and 7 inert tablets (Mercilon 28)
Ethinyloestradiol 20 mcg with desogestrel 150mcg and 7 inert tablets (Mercilon 28) will be fully funded from 14 December 2020 until 28 February 2021.
23 November 2020 update
Until now Mercilon 28 has been partially funded for most patients or fully funded as a second line treatment for low income patients. PHARMAC’s expert clinical advisors have told us that Mercilon 28 may be a suitable alternative combined oral contraceptive for patients who cannot tolerate combined oral contraceptives containing ethinyloestradiol with levonorgestrel (Microgynon 20 ED and Levlen ED), or where a progesterone only pill or long acting reversible contraceptive is unsuitable.